On May 18, 2022 DURECT Corporation (Nasdaq: DRRX) reported that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity Research at H.C. Wainwright (Press release, DURECT, MAY 18, 2022, https://investors.durect.com/news-releases/news-release-details/durect-corporation-present-hc-wainwright-global-investment [SID1234614822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast link of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

Management will also be available for virtual 1×1 meetings from May 23-25, 2022 during the conference. If attendees would like to request a meeting, please contact H.C. Wainwright directly.